X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PLETHICO PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PLETHICO PHARMA DR. REDDYS LAB/
PLETHICO PHARMA
 
P/E (TTM) x 22.5 -1.1 - View Chart
P/BV x 3.1 0.0 18,328.9% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 DR. REDDYS LAB   PLETHICO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
PLETHICO PHARMA
Mar-14
DR. REDDYS LAB/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875395 728.0%   
Low Rs1,88831 6,031.9%   
Sales per share (Unadj.) Rs930.2604.4 153.9%  
Earnings per share (Unadj.) Rs117.432.5 361.5%  
Cash flow per share (Unadj.) Rs185.851.3 361.9%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.4473.6 178.3%  
Shares outstanding (eoy) m166.0734.08 487.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.60.4 726.1%   
Avg P/E ratio x20.36.6 309.1%  
P/CF ratio (eoy) x12.84.2 308.8%  
Price / Book Value ratio x2.80.5 626.7%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,4967,262 5,445.8%   
No. of employees `00022.0NA-   
Total wages/salary Rs m33,5621,596 2,102.9%   
Avg. sales/employee Rs Th7,032.8NM-  
Avg. wages/employee Rs Th1,527.9NM-  
Avg. net profit/employee Rs Th887.7NM-  
INCOME DATA
Net Sales Rs m154,48220,598 750.0%  
Other income Rs m3,375386 873.6%   
Total revenues Rs m157,85720,984 752.3%   
Gross profit Rs m31,7822,818 1,128.0%  
Depreciation Rs m11,348642 1,766.8%   
Interest Rs m8891,593 55.8%   
Profit before tax Rs m22,920969 2,366.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858-138 -2,788.0%   
Profit after tax Rs m19,5001,107 1,761.7%  
Gross profit margin %20.613.7 150.4%  
Effective tax rate %16.8-14.3 -117.8%   
Net profit margin %12.65.4 234.9%  
BALANCE SHEET DATA
Current assets Rs m111,10118,877 588.6%   
Current liabilities Rs m58,97311,896 495.7%   
Net working cap to sales %33.733.9 99.6%  
Current ratio x1.91.6 118.7%  
Inventory Days Days7936 220.8%  
Debtors Days Days94198 47.6%  
Net fixed assets Rs m101,2459,861 1,026.8%   
Share capital Rs m830341 243.6%   
"Free" reserves Rs m139,40612,331 1,130.6%   
Net worth Rs m140,23616,139 868.9%   
Long term debt Rs m22,0004,706 467.5%   
Total assets Rs m224,65633,146 677.8%  
Interest coverage x26.81.6 1,665.6%   
Debt to equity ratio x0.20.3 53.8%  
Sales to assets ratio x0.70.6 110.7%   
Return on assets %9.18.1 111.4%  
Return on equity %13.96.9 202.7%  
Return on capital %14.912.3 121.6%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m88,6734,402 2,014.2%   
Fx outflow Rs m19,1043,184 600.0%   
Net fx Rs m69,5691,219 5,709.4%   
CASH FLOW
From Operations Rs m28,7042,437 1,177.6%  
From Investments Rs m-7,727-6,265 123.3%  
From Financial Activity Rs m-21,3262,490 -856.4%  
Net Cashflow Rs m-314-1,337 23.5%  

Share Holding

Indian Promoters % 25.5 82.7 30.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.3 125.6%  
FIIs % 35.3 5.5 641.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 7.5 204.0%  
Shareholders   75,885 10,665 711.5%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Sensex Ends 48 Points Lower(Closing)

After opening the day on a flat note, share markets in India witnessed selling pressure during closing hours and ended marginally lower.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 23, 2019 03:35 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS